• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[环孢素用于重症溃疡性结肠炎]

[Cyclosporin for severe ulcerative colitis].

作者信息

Symon Z, Stalnikowich R, Eliakim R, Ackerman Z, Rachmilewitz D

机构信息

Dept. of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem.

出版信息

Harefuah. 1997 Jan 15;132(2):77-80, 152.

PMID:9119304
Abstract

In recent years there have been numerous reports of successful treatment of resistant ulcerative colitis with cyclosporin. A series of 9 patients with moderate to severe active ulcerative colitis was treated with cyclosporin between September 1993 and October 1994. All 9 had failed to respond to conventional therapy, including salazopyrine and intravenous corticosteroids. They underwent colonoscopy and after contraindications to therapy were ruled out, received intravenous cyclosporin, 4 mg/kg/day for 7-10 days. They were discharged on oral cyclosporin with average serum levels maintained at 200 ng/ml. Response was assessed using the clinical score system of Schroeder et al. 2 out of 9 patients (22%) responded with full clinical remissions lasting more than 6 months. 6 patients had partial responses to the intravenous therapy, but symptoms resumed shortly after its cessation. Factors predicting favorable response to cyclosporin therapy were a shorter duration of disease with a fulminant clinical course. The success rate was less than that reported in the literature, possibly because of comparatively low serum cyclosporin levels. Potential complications of therapy and high cost preclude the routine use of cyclosporin in ulcerative colitis. Larger controlled studies are required to assess its efficacy and safety. Until such studies are available, cyclosporin may be tried in poor surgical risks or those not yet ready psychologically for total colectomy.

摘要

近年来,有大量关于用环孢素成功治疗难治性溃疡性结肠炎的报道。1993年9月至1994年10月期间,对9例中重度活动性溃疡性结肠炎患者进行了环孢素治疗。这9例患者对包括柳氮磺胺吡啶和静脉用皮质类固醇在内的传统治疗均无反应。他们接受了结肠镜检查,在排除治疗禁忌证后,接受静脉用环孢素,剂量为4毫克/千克/天,持续7至10天。出院时给予口服环孢素,平均血清水平维持在200纳克/毫升。使用施罗德等人的临床评分系统评估反应。9例患者中有2例(22%)完全临床缓解,持续超过6个月。6例患者对静脉治疗有部分反应,但停药后不久症状复发。预测对环孢素治疗反应良好的因素是病程较短且临床过程暴发性。成功率低于文献报道,可能是因为血清环孢素水平相对较低。治疗的潜在并发症和高成本妨碍了环孢素在溃疡性结肠炎中的常规使用。需要进行更大规模的对照研究来评估其疗效和安全性。在有此类研究之前,对于手术风险高或心理上尚未准备好接受全结肠切除术的患者,可以尝试使用环孢素。

相似文献

1
[Cyclosporin for severe ulcerative colitis].[环孢素用于重症溃疡性结肠炎]
Harefuah. 1997 Jan 15;132(2):77-80, 152.
2
Cyclosporin for severe ulcerative colitis.
Isr Med Assoc J. 2000 Aug;2(8):588-91.
3
Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis.环孢素联合促肾上腺皮质激素治疗难治性溃疡性结肠炎的疗效
Hepatogastroenterology. 2003 Jan-Feb;50(49):91-4.
4
Cyclosporin for the treatment of severe ulcerative colitis.
Z Gastroenterol. 1994 Mar;32(3):137-40.
5
Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis.环孢素治疗重度溃疡性结肠炎患者的短期疗效及长期预后
Z Gastroenterol. 1998 Apr;36(4):287-93.
6
[Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].[环孢素A治疗对类固醇难治性慢性炎症性肠病患者的疗效]
Wien Klin Wochenschr. 1998 Sep 4;110(16):579-84.
7
Cyclosporin for severe ulcerative colitis attacks.环孢素用于重度溃疡性结肠炎发作。
Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxcviii-ccc.
8
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.环孢素用于对类固醇治疗无效的重度溃疡性结肠炎。
N Engl J Med. 1994 Jun 30;330(26):1841-5. doi: 10.1056/NEJM199406303302601.
9
Outcome of a conservative approach in severe ulcerative colitis.重度溃疡性结肠炎保守治疗的结果
Dig Liver Dis. 2004 Jan;36(1):21-8. doi: 10.1016/j.dld.2003.04.001.
10
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.重度、激素抵抗型溃疡性结肠炎对环孢素治疗反应的预测因素。
Am J Gastroenterol. 2000 Aug;95(8):2000-8. doi: 10.1111/j.1572-0241.2000.02186.x.